CannaPharmARx, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $1,645,647 for the nine months ended on that date alongside a shareholders' deficit exceeding $30 million.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $1,645,647 for the nine months ended September 30, 2026, compared to a net loss of $3,581,863 for the same period in 2025, according to the filing.
  • Third-quarter net income: For the three months ended September 30, 2026, the company reported net income of $645,416, driven in part by a $1,728,677 change in the fair value of the derivative conversion feature.
  • Revenue decline: Revenue for the nine months ended September 30, 2026 was $1,041,385, down from $1,223,533 for the same period in 2025.
  • Accumulated deficit: The accumulated deficit stood at $113,961,237 as of September 30, 2026, up from $112,315,590 at December 31, 2025.
  • Total shareholders' deficit: Total shareholders' deficit was $(30,186,090) as of September 30, 2026, compared to $(30,153,729) at December 31, 2025.
  • Shares outstanding: Common shares outstanding as of November 10, 2026 were 708,689,905, as stated on the cover page of the filing.
  • Related-party loans: Loans payable to related parties, current portion, totaled $14,382,683 as of September 30, 2026, compared to $12,567,911 at December 31, 2025.

CannaPharmARx Financial Results for the Quarter and Nine Months Ended September 30, 2026

According to the Form 10-Q filed with the U.S. Securities and Exchange Commission for the period ended September 30, 2026, CannaPharmARx, Inc. (OTC Pink Sheets:CPMD) reported a gross loss of $693,142 for the nine months ended September 30, 2026, on revenue of $1,041,385 and cost of goods sold of $1,734,527. For the same nine-month period in 2025, the company disclosed revenue of $1,223,533 and a gross loss of $1,367,918. The filing noted that inventory impairment losses of $864,567 were included in cost of goods sold for the nine months ended September 30, 2026.

For the three months ended September 30, 2026, the registrant reported net income of $645,416, compared to a net loss of $1,477,811 in the prior-year quarter. The filing attributed a significant portion of the quarterly swing to non-cash items: a change in the fair value of the derivative conversion feature contributed $1,728,677 in income, and a change in the fair value of the obligation to issue shares contributed $181,693. Interest expense for the three months ended September 30, 2026 was $(458,291), with an additional imputed interest expense to related parties of $(274,357).

As of September 30, 2026, the company disclosed total assets of $7,288,551 and total liabilities of $37,474,641, resulting in a total shareholders' deficit of $(30,186,090). Current liabilities included accounts payable and accrued liabilities of $10,692,418, accrued interest of $2,649,559, and convertible notes of $1,017,004. The filing identifies the company as a smaller reporting company and a non-accelerated filer incorporated in Delaware, with its principal executive offices located in Mountain View County, Alberta, Canada.

What Was Disclosed

CannaPharmARx, Inc. filed its unaudited 10-Q for the quarter ended September 30, 2026, reporting a nine-month net loss of $1,645,647, an accumulated deficit of $113,961,237, and total liabilities of $37,474,641 against total assets of $7,288,551.